Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 901–1,000 of 1,000
Recent advances in nanoparticle-based approaches for the treatment of multiple myeloma
Oprea, M., Voicu, Ș. I., & Ionita, M. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102849 · Cited by 3
Karpenko, D. V., Петинати, Н. А., Дризе, Н. И., & Bigildeev, A. (2021) · Гематология и трансфузиология · doi:10.35754/0234-5730-2021-66-2-263-279 · Cited by 3
Furze, R. C., Molnár, M. J., Parr, N. J., Ahmad, F. F., Henry, Y., Howe, D. C., Singh, R. P., Toal, M., Bassil, A. K., Bernard, S. G., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15428 · Cited by 3
The effects of valproic acid on skin healing: experimental study in rats
Biondo-Simões, R., Biondo-Simões, M. D. L. P., Ioshii, S. O., Robes, R. R., & DALL’ANTONIA, M. O. (2022) · Acta Cirúrgica Brasileira · doi:10.1590/acb370403 · Cited by 3
Kwesi‐Maliepaard, E. M., Malik, M., van Welsem, T., van Doorn, R., Vermeer, M. H., Vlaming, H., Jacobs, H., & van Leeuwen, F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1032958 · Cited by 3
Molecular Approaches for the Detection of DNA Methylation
Smail, H. O., & Mohamad, D. (2022) · Academic Journal of Nawroz University · doi:10.25007/ajnu.v11n4a1225 · Cited by 3
“HDAC inhibitors provoke the arrest of cancer cell cycles (Eckschlager et al., 2017).”
BackgroundAdvances in Hodgkin’s lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors
Ho, T. N., Coleman, C. L., Shah, P., & Yazbeck, V. Y. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2219392 · Cited by 4
“HDAC inhibitors (HDACIs) play a role in activating cell cycle arrest, intrinsic and extrinsic apoptosis pathways, and decreasing angiogenesis [18,19,30].”
BackgroundEpigenetic (De)regulation in Prostate Cancer
Xu, C., Zhao, S., & Cai, L. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_10 · Cited by 4
Park, S., Kim, D., Jung, H., Choi, I., Kwon, H., & Lee, Y. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.104 · Cited by 3
Senthilkumar, P., Gogoi, B., Dhan, S. S., Subramani, R., Pushparaj, C., & Mahesh, A. (2024) · Drug Development Research · doi:10.1002/ddr.22172 · Cited by 4
“Additionally, HDIs apply their influence on nonhistone targets, including transcription factors (Eckschlager et al., 2017; Li et al., 2012; McLeod et al., 2017; Yu, Li, et al., 2020; Zhang & Zhou, 2012), hormonal receptors (Limagne et al., 2017), and signaling mediators (Limagne et al., 2017;…”
BackgroundThe potential of dibenzazepine carboxamides in cancer therapy
Afsordeh, N., Pournajaf, S., Mirnajafi‐Zadeh, J., & Pourgholami, M. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1564911 · Cited by 4
Uchiumi, F. (2018) · InTech eBooks · doi:10.5772/intechopen.71701 · Cited by 4
Discovery of Small Molecule Inhibitors for Histone Methyltransferases in Cancer
Motolani, A., Sun, M., Martin, M., Sun, S., & Lu, T. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.92830 · Cited by 4
Senawong, T., Saenglee, S., Senawong, G., Jeeunngoi, J., Jogloy, S., Ketterman, A. J., & Sripa, B. (2020) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/2221-1691.287163 · Cited by 4
Yahaya, T., Oladele, E. O., Muhammed, A., Haruna, A., & Liman, U. U. (2021) · Pharmaceutical and Biomedical Research · doi:10.18502/pbr.v7i3.7697 · Cited by 3
Lyu, W., Mi, D., Vinson, P. N., Xiao, Y., & Zhang, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158400 · Cited by 3
“HDAC inhibitors work by tipping the HDAC/HAT balance, leading to relaxation of the chromatin structure and enhanced gene transcription [46].”
BackgroundSundaramurthi, H., Giricz, Z., & Kennedy, B. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169378 · Cited by 3
Sullivan, J., Feng, Z., Fahey, P. P., Agho, K., Hurley, S. P., & LIM, D. J. (2022) · JBI Evidence Synthesis · doi:10.11124/jbies-21-00466 · Cited by 3
HDAC1-Mediated Downregulation of NEU1 Exacerbates the Aggressiveness of Cervical Cancer
Xie, N., Mei, S., Dai, C., & Chen, W. (2024) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2023051396 · Cited by 3
Epigenetics and Lifestyle: The Impact of Stress, Diet, and Social Habits on Tissue Homeostasis
Pérez, R. F., Santamarina‐Ojeda, P., Fernández, A. F., & Fraga, M. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814879-2.00020-0 · Cited by 6
Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase
Padilla‐Coley, S., Rudebeck, E. E., Smith, B. D., & Pfeffer, F. M. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128207 · Cited by 3
Deng, M., Xiao, H., Peng, H., Yuan, H., Xiao, X., & Liu, S. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04554-6 · Cited by 3
“Cell-cycle arrest is the first HDAC inhibitor function to be identified in tumor cells [37].”
BackgroundHigh-Throughput Screening for Epigenetic Compounds That Induce Human β-Defensin 1 Synthesis
Lyu, W., Deng, Z., & Zhang, G. (2023) · Antibiotics · doi:10.3390/antibiotics12020186 · Cited by 5
“Notably, a majority of epigenetic compounds are being developed as anticancer drugs [16].”
BackgroundDNA Methylation in Mammalian Cells
Winata, P., William, M., Keena, V. A., Takahashi, K. L., & Cheng, Y. Y. (2018) · InTech eBooks · doi:10.5772/intechopen.72991 · Cited by 4
“A list of these agents is summarised in Table 1a and Table 1b [114, 115].”
BackgroundElmezayen, A. D., Al-Obaidi, A., & Yelekçi, K. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.107937 · Cited by 4
Developing Ligands to Target Transition Metals in Cancer
Utterback, R. D., & Tomat, E. (2019) · Wiley eBooks · doi:10.1002/9781119951438.eibc2694 · Cited by 7
Valproic acid in glioma: Will the anticancer issue ever be solved?
van der Meer, P. B., & Koekkoek, J. A. F. (2022) · Neuro-Oncology Practice · doi:10.1093/nop/npac091 · Cited by 3
Knoedler, L., Huelsboemer, L. F., Hollmann, K., Alfertshofer, M. G., Herfeld, K., Hosseini, H. C., Boroumand, S., Stögner, V. A., Safi, A., Perl, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1276306 · Cited by 4
“An interaction between HDAC inhibitors and the multi-kinase inhibitor pazopanib, both in vitro and in vivo , has been recently evidenced to induce apoptosis in sarcoma cells and decrease tumor growth (175 – 177).”
BackgroundBarone, P., Bottaro, A., Leanza, R., Stagno, F., & Allegra, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040227 · Cited by 2
Zhong, L., Purushothaman, B., Tu, Q., Boopathi, S., & Zhang, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144427 · Cited by 4
Zhang, Y., Cao, X., Li, W., Cui, Z., Mao, J., Yao, R., & Liu, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116998 · Cited by 3
Shirbhate, E., Koch, B., Singh, V., Dubey, A., Yasin, H. K. A., & Rajak, H. (2025) · Pharmaceuticals · doi:10.3390/ph18081148 · Cited by 3
“Numerous promising HDAC inhibitors are under various phases of clinical investigations against different malignancies [20].”
Dung, N. P., Kim, H. K., Huyen, V. T. M., Kang, D. H., Kim, H. Y., Kang, J. S., Anh, D. T., Tùng, T. T., Han, S., & Nam, N. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143653 · Cited by 3
Bao, Y., Li, J., zhang, A., Ni, Y., Bi, M., & Chen, J. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111777 · Cited by 3
Li, Y., Li, D., Chen, J., Gao, Y., Zou, X., Li, H., Yu, Z., Zou, Y., & Guo, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102418 · Cited by 5
Zhang, Q., Ma, Y., Ding, Y., Li, Z., Gao, S., Ju, J., & Zhao, C. (2026) · ONCOLOGIE · doi:10.1515/oncologie-2025-0419 · Cited by 2
“These HDAC-containing complexes mediate epigenetic silencing through two distinct mechanisms, namely, sequence-speci fi c transcriptional repression and constitutive chromatin binding [14].”
Therapeutic Potential of HDAC Inhibitors in Neurodegenerative Diseases
Singh, A. K., Sudhan, Y. G., Chandana, S. L., Iyaswamy, A., & Durairajan, S. S. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-6099-8_14 · Cited by 2
Xia, W., Jiang, M., Huang, Y., Ding, K., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70655 · Cited by 2
“Panobinostat (LBH 589) has been approved for the treatment of MM [ 323 ].”
Sun, J., Yang, F., Li, Y., Li, S., & Song, J. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218527 · Cited by 3
George, G., Garmo, H., Adolfsson, J., Elf, K., Gedeborg, R., Holmberg, L., Stattin, P. E., Styrke, J., & Hemelrijck, M. V. (2023) · Journal of Oncology · doi:10.1155/2023/9527920 · Cited by 2
“Tis renders them to be promising anticancer drugs, particularly in combination with other anticancer drugs and/or radiotherapy [5].”
BackgroundDutta, M., Qamar, T., Kushavah, U., Siddiqi, M. I., & Kar, S. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10824-w · Cited by 3
Abolished clustering of MeCP2T158M can be partially reverted with small molecules
Lata, R., Steegmans, L., Kellens, R., Nijs, M., Klaassen, H., Versele, M., Christ, F., & Debyser, Z. (2024) · Translational Medicine Communications · doi:10.1186/s41231-024-00176-w · Cited by 2
“Currently HDACis are used to treat different cancers such as lymphoma or myeloma or neurological disorders such as epilepsy or bipolar disorders [40].”
BackgroundBiondo-Simões, R., Biondo-Simões, M. D. L. P., Ioshii, S. O., Robes, R. R., DALL’ANTONIA, M. O., GOEHR, M. P., & Neves, P. J. F. (2024) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20243676 · Cited by 2
Liu, J., Yen, C., Lin, Y., Feng, Y., & Fang, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s475823 · Cited by 2
Wen, K.-Y., Zhu, W., Luo, Z., & Wang, W. (2024) · Discover Oncology · doi:10.1007/s12672-024-01713-7 · Cited by 2
Komariah, K., Ageng, A., & Kusuma, I. (2019) · Prosiding Seminar Nasional Pakar · doi:10.25105/pakar.v0i0.4143 · Cited by 2
Peng, Y., Li, Y., Lo, H. H., Law, B. Y. K., & Wong, V. K. W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_6 · Cited by 2
Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma
Pickering, O. J., Breininger, S. P., Underwood, T., & Walters, Z. S. (2021) · Cancers · doi:10.3390/cancers13164084 · Cited by 2
“Finally, the lack of specific biomarkers for patient selection for HDACi treatment may also be limiting progression, although this has not been a limitation in other cancer types [66,67].”
BackgroundLow, C. H., Mohamad, H., Mustafa, S. F. Z., Mohd, K. S., & Nafi, N. E. M. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103510 · Cited by 2
Recent Advances In Breast Cancer Treatments
Wasserman, A., Wasserman, E., & Mak, R. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v10i4.2123 · Cited by 2
Mikesova, J., Ondrakova, M., Jelínková, I., Ptáček, J., Nováková, Z., & Bařinka, C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2788-4_29 · Cited by 2
Malise, T. T. A., Nweke, E. E., Takundwa, M. M., Fru, P., & Raj, D. B. T. G. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_775 · Cited by 2
SYNTHESIS, SPECTROSCOPIC, THERMAL AND BIOLOGICAL STUDIES of SOME NOVEL METAL IONS COMPLEXES
Abbas, A. K. (2022) · MINAR International Journal of Applied Sciences and Technology · doi:10.47832/2717-8234.12.33 · Cited by 2
Impact of the microbiome on colorectal cancer development
Chorawala, M. R., Postwala, H. I., Prajapati, B. G., Shah, Y. B., Shah, A. C., Pandya, A. J., & Kothari, N. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00021-0 · Cited by 2
Design, synthesis and activity evaluation of arctigenin derivatives with HDAC inhibition activity
Jiang, X., Yan, Y., Yang, H., Cheng, M., Dou, D., & Liu, Y. (2024) · RSC Advances · doi:10.1039/d4ra00050a · Cited by 2
Identification of Fatty Acid Metabolism-Related Subtypes in Gastric Cancer Aided by Machine Learning
Hou, M., Chen, J., Yang, L., Qin, L. Y., Liu, J., Zhao, H., Guo, Y., Yu, Q., & Zhang, Q. (2024) · Cancer Management and Research · doi:10.2147/cmar.s483577 · Cited by 2
“25 VPA is not only used in anticonvulsant therapy 26 , but it may also become a potential therapeutic drug for gastric cancer.”
BackgroundEpigenetic modifications control CYP1A1 Inducibility in human and rat keratinocytes
Lin, L.-W., Ehrlich, A. K., & Rice, R. H. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117163 · Cited by 2
The histone deacetylase inhibitor Scriptaid targets G-quadruplexes
Sánchez-Martín, V., Ružić, D., Tello-Lopez, M. J., Ortiz-Morales, A., Murciano‐Calles, J., Soriano, M., Nikolic, K. M., & Garcia-Salcedo, J. A. (2025) · Open Biology · doi:10.1098/rsob.240183 · Cited by 2
“We have examined only one HDACI, while there is a broad group of HDACIs discovered [51] which could be explored as G4 ligands in future studies.”
Histone modification inhibitors: An emerging frontier in thyroid Cancer therapy
Wang, Q., Sun, S. W., Sun, G., Han, B., Zhang, S., Zheng, X., & Chen, L. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111703 · Cited by 5
Dews, E. A., Teixeira, J. E., Huston, C. D., Meyers, M. J., & Hyson, P. R. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-25 · Cited by 3
“Panobinostat has been approved as an oral treatment for multiple myeloma, and other HDAC inhibitors have been used for numerous forms of both solid organ and hematologic malignancy (29).”
Al-Khafaji, A. S., Qaddoori, Y. B., Alabdei, H. H., & Wang, L. M. (2025) · Biomedical Reports · doi:10.3892/br.2025.2013 · Cited by 2
“So far, four HDAC inhibitors (HDACis) have been approved by the Food and Drug Administration for clinical use and there are more undergoing clinical trials (34).”
Ghosh, R., Kundu, M., & Chattopadhyay, S. K. (2025) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202500232 · Cited by 2
Buyan, M. I., Pevzner, I. B., Buyan, A., Zorova, L. D., Zorov, D. B., Andrianova, N. V., & Plotnikov, E. Y. (2025) · IUBMB Life · doi:10.1002/iub.70044 · Cited by 2
“HDACs inhibitors have long been researched as effective anti-tumor agents; several drugs from this group have already been approved for clinical practice [23].”
Wen, Z., Duan, Y., Xiong, Y., & Huang, Y. P. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128270 · Cited by 2
Epigenetics Involvement in Breast Cancer
Khan, M. A. (2022) · Springer eBooks · doi:10.1007/978-981-19-0197-3_8 · Cited by 2
Clinical Applications of Histone Deacetylase Inhibitors
Pacaud, R., García, J., Thomas, S., & Münster, P. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91909-8.00002-5 · Cited by 2
Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma
Akiyama, T., Yoshimatsu, Y., Noguchi, R., Sin, Y., Osaki, J., Adachi, Y., Ono, T., Tsuchiya, R., Sato, C., Iwata, S., et al. (2022) · Human Cell · doi:10.1007/s13577-022-00828-9 · Cited by 2
“Romidepsin is a histone deacetylase (HDAC) inhibitor that exerts antitumor effects on various tumors [28].”
MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER+ Breast Cancer
Wörthmüller, J., Disler, S., Pradervand, S., Richard, F., Haerri, L., Buendía, G. A. R., Fournier, N., Desmedt, C., & Rüegg, C. (2023) · Cells · doi:10.3390/cells12151929 · Cited by 3
“The use of HDAC inhibitors can reactivate epigenetically silenced genes [95] and thus represent a promising strategy for cancer therapy, particularly in combination with cytotoxic agents and/or radiotherapy [136].”
BackgroundTasneem, S., Alam, M. M., Parvez, S., Pinky, P., Khan, F., Garg, M., Amir, M., Akhter, M., Amin, S., Khan, M. A., et al. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0105 · Cited by 2
HDAC inhibitors: A novel approach to hyperglycaemia management and treatment
Suchitra, M., Kusuma, P. K., Katagi, M. S., Venkateswarlu, G., & Mahalakshmi, P. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100137 · Cited by 5
Tuncer, Z., Kurar, E., & Duran, T. (2024) · Saudi Medical Journal · doi:10.15537/smj.2024.45.2.20230478 · Cited by 2
Regulation of HDACi−Triggered Autophagy by the Tumor Suppressor Protein p53
Mrakovcic, M., & Fröhlich, L. F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86911 · Cited by 3
Is Na+ channel blocker increase vincristine antitumor effect on neuroblastoma?
Taghizadehghalehjoughi, A. (2019) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.6050 · Cited by 2
Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_8 · Cited by 2
Khan, A. A., Khattak, M. N. K., Parambath, D., & El-Serafi, A. T. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.08.033 · Cited by 2
Kaur, N. (2023) · Advances In Clinical And Medical Research · doi:10.52793/acmr.2023.4(3)-58 · Cited by 2
Tying Metabolic Branches With Histone Tails Using Systems Biology
Chandrasekaran, S. (2019) · Epigenetics Insights · doi:10.1177/2516865719869683 · Cited by 2
Wang, C., Li, C., Huang, R.-C., Li, Y.-H., Liou, J., & Tsai, S. (2020) · doi:10.21203/rs.3.rs-70831/v1 · Cited by 2
Genetic modifiers of APOBEC-induced mutagenesisPreprint
Mertz, T. M., Rice-Reynolds, E., Nguyen, L. T. H., Wood, A. J., Bray, N., Mitchell, D., Lobachev, K. S., & Roberts, S. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.05.535598 · Cited by 2
“…to reduce H3K56Ac (Liu et al. 2012), and a large number of clinical trials for HDAC inhibitors that likely increase H3K56Ac levels in tumor cells (Eckschlager et al. 2017), all of which effect patient prognosis and influence therapeutic outcomes by increasing APOBEC-induced mutagenesis and for…”
BackgroundEpigenetic alterations in female urogenital organs cancer: Premise, properties, and perspectives
Ahmed, A. A., & Essa, M. E. A. (2020) · Scientific African · doi:10.1016/j.sciaf.2020.e00318 · Cited by 1
Histone deacetylase inhibitors providing an epigenetic treatment in cancer
Cinek, T., & Karalı, N. (2021) · Istanbul Journal of Pharmacy · doi:10.26650/istanbuljpharm.2021.904686 · Cited by 2
The role of epigenetics in cancer metastasis
Farmer, M., Redd, K., Roberson, T., Smith, M., & Lewis, K. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821789-4.00021-7 · Cited by 1
A neuronal cell-based reporter system for monitoring the activity of HDAC2
Unemura, K., Kawano, M., Takakura, M., Iwata, I., Hyakkoku, K., Horiguchi, N., Okuda, T., & Hirano, Y. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.10.001 · Cited by 1
Gnedina, O. O., Morshneva, A. V., & Igotti, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115913 · Cited by 1
“NaBut alone does not activate caspases 3, 8, and 9.”
BackgroundInfluentialSpirin, P., Vedernikova, V., Volkava, T., Morozov, A. V., Kleymenova, A. A., Zemskaya, A. S., Shyrokova, L., Porozov, Y. B., Glumakova, K. A., Lebedev, T. D., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040416 · Cited by 1
“Pan-HDAC inhibitors have been shown to suppress the survival of cancer cells from various origins [49,50]. origins [49,50].”
Kalsum, S., Xu, R., Akber, M., Huang, S., Lerm, M., Chen, Y., Lourda, M., Zhou, Y., & Brighenti, S. (2025) · Biomolecules · doi:10.3390/biom15040550 · Cited by 1
“HDAC inhibitors, classified into five structural groups, block HDACs to maintain histone acetylation, which typically results in an altered gene expression profile of the cell [11].”
Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo
Shen, C., Wu, J., Wang, S., Liu, H.-T., Wu, P., Chan, K., Huang, S., Lee, M., & Liu, Y. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118108 · Cited by 1
Leveraging chicken embryos for studying human enhancers
Williams, R. M. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2025.05.009 · Cited by 1
Loss of negative regulation by HDAC1 and REST contributes to MAD1 overexpression in breast cancer
Copeland, S. E., Chen, B., Roopra, A., & Weaver, B. A. A. (2025) · Molecular Biology of the Cell · doi:10.1091/mbc.e24-12-0582 · Cited by 1
“VPA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of epilepsy, bipolar disorder, and migraines (Eckschlager et al. , 2017).”
Epigenetic Parameters as Potential Prognostic and Therapeutic Factors in Neurodegenerative Diseases
Słowikowski, B. K., Owecki, W., Poszwa, J., Jezierski, M., Draguła, M., Goutor, U., Jagodziński, P. P., Kozubski, W. P., & Dorszewska, J. (2025) · RNA technologies · doi:10.1007/978-3-031-91072-2_7 · Cited by 2
Wen, B., Feng, S., Bao, L., Li, S., Yang, Y., Long, S., Xiao, J., Li, S., Hou, Y., & Liu, S. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114667 · Cited by 1
Wnt signal pathways: new mechanistic approaches and clinical horizons in cancer therapy
Hassan, H. A., & Abdel-Sater, K. A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02868-1 · Cited by 1
Insights into histone deacetylase inhibitors-induced cell death in cancer cell lines
Fuentes-Baile, M., García-Morales, P., Pérez-Valenciano, E., Mata‐Balaguer, T., Menéndez-Gutierrez, M. P., Romero, C. D. J., Lescure, Á. R., Martín‐Orozco, E., Mallavia, R. M., Barberá, V. M., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118541 · Cited by 3
Choi, Y. M., Jang, Y., Choi, S., Park, Y. S., Oh, S.-Y., & Jo, I. (2025) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-025-00763-4 · Cited by 1
“Considering that MPA has exhibited the potential to inhibit HDAC expression, which involves in the differentiation of various cells [3, 4, 11–15], it is reasonable to speculate that MPA could serve as a potential modulator of cell differentiation.”
Ramadan, W. S. H., Menon, V., Zein, R. A., Alqedra, S., El-Gharib, Y., Al-Shihabi, A. M., Alhamidi, R. S., İlçe, B. Y., Hamoudi, R., & El‐Awady, R. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117535 · Cited by 2
Investigation of the histone deacetylase inhibitor potential of phorbazole analogues
Reierth, I. A. N., Guttormsen, Y., Andersen, J. H., Hansen, E. H., Abdelhady, A. M., Langer, M. K., Haug, B. E., Bayer, A., & Petit, G. A. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118489 · Cited by 1
Wu, Q., Zhao, Y., Yu, Q., Ding, J., Sun, C., Wei, X., Li, S., Wang, K., Zhou, R., Yao, F., et al. (2025) · Cell Biology International · doi:10.1002/cbin.70105 · Cited by 1
“In addition, HDACIs exhibit therapeutic potential in leukemia by inducing apoptosis through ROS generation across multiple leukemic cell lines (Jurkat, ML ‐ 1, U937, HL ‐ 60, K ‐ 562, CEM ‐ CCRF) (Eckschlager et al. 2017).”
Targeted therapy in KMT2Ar AML
Zhang, Y., Yang, Y.-K., Du, Y., Tang, Y., & Gong, Y. (2025) · Hematology · doi:10.1080/16078454.2025.2599585 · Cited by 1
Yang, L. M. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111081 · Cited by 2
“Both HDAC inhibition (84) and modulation of the extra-cellular tumor environment via hypotonic solutions (85) have been used or are potential methods for cancer treatment.”
Smith, K. H., Trovillion, E. M., McKinney, K. Q., Gourabathini, P., Wells, K., Gandra, D., Sholler, C., Votruba, I., Oesterheld, J. E., & Sholler, G. L. S. (2025) · Cancers · doi:10.3390/cancers17244018 · Cited by 1
“HDAC inhibitors are clinically available, though none are approved for use in pediatric sarcomas [17,23].”
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
